Actinium Pharmaceuticals, Inc. (ATNM) financial statements and ratios from SEC XBRL: revenue $90000.00 (TTM), net margin -37652.2%, revenue growth -97.7% YoY, P/E 3.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $90000.00 |
| Net Margin | -37652.2% |
| Revenue Growth (YoY) | -97.7% |
| EPS Growth (YoY) | -14.2% |
| FCF Growth (YoY) | -25.4% |
| P/E Ratio | 3.0 |
| EV / EBITDA | -0.2 |
| Price / Book | 1.15 |
| Price / Sales | 0.97 |
| FCF Yield | -66.7% |
| Altman Z-Score | -11.95 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ATNM overview · ATNM earnings · ATNM KPIs · ATNM investor relations · ATNM ownership · ATNM peers · ATNM filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.